STAT5A/B gene locus undergoes amplification during human prostate cancer progression

American Journal of Pathology

Volumn 182, Issue 6, 2013, Pages 2264-2275

  Haddad, Bassem R ^a   Gu, Lei ^b   Mirtti, Tuomas ^d   Dagvadorj, Ayush ^b   Vogiatzi, Paraskevi ^b   Hoang, David T ^b   Bajaj, Renu ^c   Leiby, Benjamin ^c   Ellsworth, Elyse ^b   Blackmon, Shauna ^b   Ruiz, Christian ^e   Curtis, Mark ^c   Fortina, Paolo ^b   Ertel, Adam ^b   Liu, Chengbao ^b   Rui, Hallgeir ^b,c   Visakorpi, Tapio ^c   Bubendorf, Lukas ^e   Lallas, Costas D ^f   Trabulsi, Edouard J ^f   McCue, Peter ^c   Gomella, Leonard ^f   Nevalainen, Marja T ^b,c,f   more..

^a GEORGETOWN UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF BASEL   (Switzerland)

^f UNIVERSITY OF TAMPERE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL INVASION; CONTROLLED STUDY; DISTANT METASTASIS; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; STAT5A GENE; STAT5B GENE;

ANIMALS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; DNA, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MICE; MICE, NUDE; NEOPLASM GRADING; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; RECURRENCE; STAT5 TRANSCRIPTION FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84878221509     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2013.02.044     Document Type: Article

References (59)

1. D.A. Loblaw, D.S. Mendelson, J.A. Talcott, K.S. Virgo, M.R. Somerfield, E. Ben-Josef, R. Middleton, H. Porterfield, S.A. Sharp, T.J. Smith, M.E. Taplin, N.J. Vogelzang, J.L. Wade Jr., C.L. Bennett, and H.I. Scher American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer J Clin Oncol 22 2004 2927 2941
2. D.A. Loblaw, K.S. Virgo, R. Nam, M.R. Somerfield, E. Ben-Josef, D.S. Mendelson, R. Middleton, S.A. Sharp, T.J. Smith, J. Talcott, M. Taplin, N.J. Vogelzang, J.L. Wade 3rd, C.L. Bennett, and H.I. Scher Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
3. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinanen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, and O.P. Kallioniemi In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat Genet 9 1995 401 406
4. K. Haapala, E.R. Hyytinen, M. Roiha, M. Laurila, I. Rantala, H.J. Helin, and P.A. Koivisto Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide Lab Invest 81 2001 1647 1651
5. M.E. Taplin, G.J. Bubley, T.D. Shuster, M.E. Frantz, A.E. Spooner, G.K. Ogata, H.N. Keer, and S.P. Balk Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer N Engl J Med 332 1995 1393 1398
6. T.M. Penning, and M.C. Byrns Steroid hormone transforming aldo-keto reductases and cancer Ann N Y Acad Sci 1155 2009 33 42
7. M.A. Titus, M.J. Schell, F.B. Lih, K.B. Tomer, and J.L. Mohler Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin Cancer Res 11 2005 4653 4657
8. R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, E. Humphreys, M. Han, A.W. Partin, R.L. Vessella, W.B. Isaacs, G.S. Bova, and J. Luo Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res 69 2009 16 22
9. Y. Li, M. Alsagabi, D. Fan, G.S. Bova, A.H. Tewfik, and S.M. Dehm Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression Cancer Res 71 2011 2108 2117
10. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR: Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715-2730
11. R.G. Pestell, and M.T. Nevalainen Prostate Cancer: Signaling Networks, Genetics and New Treatment Strategies 2008 Human Press Totowa, NJ
12. T.J. Ahonen, J. Xie, M.J. LeBaron, J. Zhu, M. Nurmi, K. Alanen, H. Rui, and M.T. Nevalainen Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells J Biol Chem 278 2003 27287 27292
13. A. Dagvadorj, S. Collins, J.B. Jomain, J. Abdulghani, J. Karras, T. Zellweger, H. Li, M. Nurmi, K. Alanen, T. Mirtti, T. Visakorpi, L. Bubendorf, V. Goffin, and M.T. Nevalainen Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway Endocrinology 148 2007 3089 3101
14. A. Dagvadorj, R.A. Kirken, B. Leiby, J. Karras, and M.T. Nevalainen Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo Clin Cancer Res 14 2008 1317 1324
15. L. Gu, A. Dagvadorj, J. Lutz, B. Leiby, G. Bonuccelli, M.P. Lisanti, S. Addya, P. Fortina, A. Dasgupta, T. Hyslop, L. Bubendorf, and M.T. Nevalainen Transcription factor Stat3 stimulates metastatic behavior of human prostate cancer cells in vivo, whereas Stat5b has a preferential role in the promotion of prostate cancer cell viability and tumor growth Am J Pathol 176 2010 1959 1972
16. A.V. Kazansky, and J.M. Rosen Signal transducers and activators of transcription 5B potentiates v-Src-mediated transformation of NIH-3T3 cells Cell Growth Differ 12 2001 1 7
17. C. Thomas, A. Zoubeidi, H. Kuruma, L. Fazli, F. Lamoureux, E. Beraldi, B.P. Monia, A.R. MacLeod, J.W. Thuroff, and M.E. Gleave Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo Mol Cancer Ther 10 2010 347 359
18. L. Gu, P. Vogiatzi, M. Puhr, A. Dagvadorj, J. Lutz, A. Ryder, S. Addya, P. Fortina, C. Cooper, B. Leiby, A. Dasgupta, T. Hyslop, L. Bubendorf, K. Alanen, T. Mirtti, and M.T. Nevalainen Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo Endocr Relat Cancer 17 2010 481 493
19. H. Li, T.J. Ahonen, K. Alanen, J. Xie, M.J. LeBaron, T.G. Pretlow, E.L. Ealley, Y. Zhang, M. Nurmi, B. Singh, P.M. Martikainen, and M.T. Nevalainen Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade Cancer Res 64 2004 4774 4782
20. H. Li, Y. Zhang, A. Glass, T. Zellweger, E. Gehan, L. Bubendorf, E.P. Gelmann, and M.T. Nevalainen Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence Clin Cancer Res 11 2005 5863 5868
21. S.H. Tan, A. Dagvadorj, F. Shen, L. Gu, Z. Liao, J. Abdulghani, Y. Zhang, E.P. Gelmann, T. Zellweger, Z. Culig, T. Visakorpi, L. Bubendorf, R.A. Kirken, J. Karras, and M.T. Nevalainen Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells Cancer Res 68 2008 236 248
22. J.N. Ihle The Stat family in cytokine signaling Curr Opin Cell Biol 13 2001 211 217
23. J. Clark, S. Edwards, A. Feber, P. Flohr, M. John, I. Giddings, S. Crossland, M.R. Stratton, R. Wooster, C. Campbell, and C.S. Cooper Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays Oncogene 22 2003 1247 1252
24. Y.K. Lee, T.D. Shanafelt, N.D. Bone, A.K. Strege, D.F. Jelinek, and N.E. Kay VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance Leukemia 19 2005 513 523
25. T. Mirtti, B.E. Leiby, J. Abdulghani, E. Aaltonen, M. Pavela, A. Mamtani, K. Alanen, L. Egevad, T. Granfors, A. Josefsson, P. Stattin, A. Bergh, and M.T. Nevalainen Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy Hum Pathol 44 2013 310 319
26. N.L. Sharma, C.E. Massie, A. Ramos-Montoya, V. Zecchini, H.E. Scott, A.D. Lamb, S. Macarthur, R. Stark, A.Y. Warren, I.G. Mills, and D.E. Neal The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man Cancer Cell 23 2013 35 47
27. A.V. Kazansky, D.M. Spencer, and N.M. Greenberg Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system Cancer Res 63 2003 8757 8762
28. T.J. Ahonen, P.L. Harkonen, H. Rui, and M.T. Nevalainen PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro Endocrinology 143 2002 228 238
29. M.T. Nevalainen, E.M. Valve, T. Ahonen, A. Yagi, J. Paranko, and P.L. Harkonen Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture FASEB J 11 1997 1297 1307
30. M.T. Nevalainen, E.M. Valve, P.M. Ingleton, M. Nurmi, P.M. Martikainen, and P.L. Harkonen Prolactin and prolactin receptors are expressed and functioning in human prostate J Clin Invest 99 1997 618 627
31. R. von Knobloch, L. Konrad, P.J. Barth, H. Brandt, S. Wille, A. Heidenreich, R. Moll, and R. Hofmann Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping Clin Cancer Res 10 2004 1064 1073
32. B.A. Verhage, K. van Houwelingen, T.E. Ruijter, L.A. Kiemeney, and J.A. Schalken Allelic imbalance in hereditary and sporadic prostate cancer Prostate 54 2003 50 57
33. K. Kasahara, T. Taguchi, I. Yamasaki, M. Kamada, K. Yuri, and T. Shuin Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization Cancer Genet Cytogenet 137 2002 59 63
34. H. Wolter, H.W. Gottfried, and T. Mattfeldt Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization BJU Int 89 2002 310 316
35. H. Wolter, D. Trijic, H.W. Gottfried, and T. Mattfeldt Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization Eur Urol 41 2002 328 334
36. J.C. Alers, J. Rochat, P.J. Krijtenburg, W.C. Hop, R. Kranse, C. Rosenberg, H.J. Tanke, F.H. Schroder, and H. van Dekken Identification of genetic markers for prostatic cancer progression Lab Invest 80 2000 931 942
37. A. Latil, J.C. Baron, O. Cussenot, G. Fournier, L. Boccon-Gibod, A. Le Duc, and R. Lidereau Oncogene amplifications in early-stage human prostate carcinomas Int J Cancer 59 1994 637 638
38. G.S. Bova, and W.B. Isaacs Review of allelic loss and gain in prostate cancer World J Urol 14 1996 338 346
39. E.M. Lange, E.M. Gillanders, C.C. Davis, W.M. Brown, J.K. Campbell, M. Jones, D. Gildea, E. Riedesel, J. Albertus, D. Freas-Lutz, C. Markey, V. Giri, J.B. Dimmer, J.E. Montie, J.M. Trent, and K.A. Cooney Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1 Prostate 57 2003 326 334
40. E.M. Gillanders, J. Xu, B.L. Chang, E.M. Lange, F. Wiklund, J.E. Bailey-Wilson, A. Baffoe-Bonnie, M. Jones, D. Gildea, E. Riedesel, J. Albertus, S.D. Isaacs, K.E. Wiley, C.E. Mohai, M.P. Matikainen, T.L. Tammela, S.L. Zheng, W.M. Brown, A. Rokman, J.D. Carpten, D.A. Meyers, P.C. Walsh, J. Schleutker, H. Gronberg, K.A. Cooney, W.B. Isaacs, and J.M. Trent Combined genome-wide scan for prostate cancer susceptibility genes J Natl Cancer Inst 96 2004 1240 1247
41. K.A. Zuhlke, J.J. Madeoy, J. Beebe-Dimmer, K.A. White, A. Griffin, E.M. Lange, S.B. Gruber, E.A. Ostrander, and K.A. Cooney Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers Clin Cancer Res 10 2004 5975 5980
42. A. El Gedaily, L. Bubendorf, N. Willi, W. Fu, J. Richter, H. Moch, M.J. Mihatsch, G. Sauter, and T.C. Gasser Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization Prostate 46 2001 184 190
43. N. Nupponen, and T. Visakorpi Molecular biology of progression of prostate cancer Eur Urol 35 1999 351 354
44. O.R. Saramaki, K.P. Porkka, R.L. Vessella, and T. Visakorpi Genetic aberrations in prostate cancer by microarray analysis Int J Cancer 119 2006 1322 1329
45. T. Zellweger, C. Ninck, M. Bloch, M. Mirlacher, P.A. Koivisto, H.J. Helin, M.J. Mihatsch, T.C. Gasser, and L. Bubendorf Expression patterns of potential therapeutic targets in prostate cancer Int J Cancer 113 2005 619 628
46. M.J. Barch, T. Knutsen, and J.L. Spurbeck The AGT Cytogenetics Laboratory Manual ed 3. 1997 Lippincott-Raven Publishers Philadelphia
47. B. Haddad, C.R. Pabon-Pena, H. Young, and W.H. Sun Assignment1 of STAT1 to human chromosome 2q32 by FISH and radiation hybrids Cytogenet Cell Genet 83 1998 58 59
48. M. Bloch, J. Ousingsawat, R. Simon, P. Schraml, T.C. Gasser, M.J. Mihatsch, K. Kunzelmann, and L. Bubendorf KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer Oncogene 26 2007 2525 2534
49. L. Bubendorf, J. Kononen, P. Koivisto, P. Schraml, H. Moch, T.C. Gasser, N. Willi, M.J. Mihatsch, G. Sauter, and O.P. Kallioniemi Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays Cancer Res 59 1999 803 806
50. A.R. Peck, A.K. Witkiewicz, C. Liu, G.A. Stringer, A.C. Klimowicz, E. Pequignot, B. Freydin, T.H. Tran, N. Yang, A.L. Rosenberg, J.A. Hooke, A.J. Kovatich, M.T. Nevalainen, C.D. Shriver, T. Hyslop, G. Sauter, D.L. Rimm, A.M. Magliocco, and H. Rui Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure J Clin Oncol 29 2011 2448 2458
51. M.T. Nevalainen, J. Xie, J. Torhorst, L. Bubendorf, P. Haas, J. Kononen, G. Sauter, and H. Rui Signal transducer and activator of transcription-5 activation and breast cancer prognosis J Clin Oncol 22 2004 2053 2060
52. M.T. Nevalainen, J. Xie, L. Bubendorf, K.U. Wagner, and H. Rui Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium Mol Endocrinol 16 2002 1108 1124
53. T.J. Ahonen, P.L. Harkonen, J. Laine, H. Rui, P.M. Martikainen, and M.T. Nevalainen Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture Endocrinology 140 1999 5412 5421
54. J.H. Kim, S.M. Dhanasekaran, R. Mehra, S.A. Tomlins, W. Gu, J. Yu, C. Kumar-Sinha, X. Cao, A. Dash, L. Wang, D. Ghosh, K. Shedden, J.E. Montie, M.A. Rubin, K.J. Pienta, R.B. Shah, and A.M. Chinnaiyan Integrative analysis of genomic aberrations associated with prostate cancer progression Cancer Res 67 2007 8229 8239
55. C.S. Grasso, Y.M. Wu, D.R. Robinson, X. Cao, S.M. Dhanasekaran, A.P. Khan, M.J. Quist, X. Jing, R.J. Lonigro, J.C. Brenner, I.A. Asangani, B. Ateeq, S.Y. Chun, J. Siddiqui, L. Sam, M. Anstett, R. Mehra, J.R. Prensner, N. Palanisamy, G.A. Ryslik, F. Vandin, B.J. Raphael, L.P. Kunju, D.R. Rhodes, K.J. Pienta, A.M. Chinnaiyan, and S.A. Tomlins The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
56. G.P. Amorino, P.D. Deeble, and S.J. Parsons Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway Oncogene 26 2007 745 756
57. V. Goffin, D.T. Hoang, R.L. Bogorad, and M.T. Nevalainen Prolactin regulation of the prostate gland: a female player in a male game Nat Rev Urol 8 2011 597 607
58. K.M. Quesnelle, A.L. Boehm, and J.R. Grandis STAT-mediated EGFR signaling in cancer J Cell Biochem 102 2007 311 319
59. C.M. Silva Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis Oncogene 23 2004 8017 8023